Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.72 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.67 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649627 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL4741208 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL1059785 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL15649602 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL23833964 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL8006368 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL25183155 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL11676490 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL7325048 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL2910119 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119113-A1 | COMPOSITIONS AND METHODS FOR SPLICEOSOME-TARGETED THERAPIES | INSTITUTE CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-06-06 | — | — | WO | claimed |
| CN-113382728-A | Age-related clonal hematopoiesis and prevention of diseases related to the same | 耶达研究及发展有限公司 | 2021-09-10 | — | — | CN | claimed |
| US-20210251955-A1 | PREVENTION OF AGE RELATED CLONAL HEMATOPOIESIS AND DISEASES ASSOCIATED THEREWITH | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-08-19 | — | — | US | claimed |
| WO-2018152095-A1 | TREATMENT OF CANCER WITH SMG1-INHIBITORS | CELGENE CORPORATION (US) | 2018-08-23 | — | — | WO | claimed |
| US-20150086694-A1 | N-Acyl-Amino Acid Derivatives for Improvement of the Flavour Profile Edible Compositions | GIVAUDAN SA (CH) | 2015-03-26 | — | — | US | claimed |
| US-20150072060-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2015-03-12 | — | — | US | claimed |
| US-20150050408-A1 | Powder Flavour Composition | GIVAUDAN SA (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2830438-A2 | N-ACYL-AMINO ACID DERIVATIVES AS FOOD FLAVOURING COMPOUNDS, POWDER COMPOSITIONS CONTAINING THEM | Givaudan SA (CH) | 2015-02-04 | — | — | EP | claimed |
| EP-2830439-A2 | N-ACYL-AMINO ACID DERIVATIVES FOR IMPROVEMENT OF THE FLAVOUR PROFILE EDIBLE COMPOSITIONS | Givaudan SA (CH) | 2015-02-04 | — | — | EP | claimed |
| WO-2013149035-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2013-10-03 | — | — | WO | claimed |
| WO-2013149012-A1 | N-ACYL AMINO ACID DERIVATIVES AS FOOD FLAVOURING COMPOUNDS | GIVAUDAN S.A. (CH) | 2013-10-03 | — | — | WO | claimed |
| WO-2013149031-A2 | POWDER FLAVOUR COMPOSITION | GIVAUDAN S.A. (CH) | 2013-10-03 | — | — | WO | claimed |
| EP-2624805-A2 | NOVEL OIL-IN-WATER COSMETIC EMULSIONS INCLUDING N-ACYLATED DERIVATIVES HAVING A HIGH MELTING POINT, AND METHODS FOR PREPARING SAME | Societe D Exploitation De Produits Pour Les Industries Chimiques Seppic (FR) | 2013-08-14 | — | — | EP | claimed |
| WO-2012042148-A2 | NOVEL OIL-IN-WATER COSMETIC EMULSIONS INCLUDING N-ACYLATED DERIVATIVES HAVING A HIGH MELTING POINT, AND METHODS FOR PREPARING SAME | SOCIETE D'EXPLOITATION DES PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2012-04-05 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| EP-4662197-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4165013-B1 | METHOD FOR PREPARING AN N-ACYL AMINO ACID BY DIRECT AMIDIFICATION OF A FATTY ACID AT HIGH TEMPERATURE | SOC DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-4016287-A | COSMETIC AND ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3971701-A | FATTY ACID, ESTER OR N-ACYLAMINO ACID SURFACTANT | AJINOMOTO CO., INC. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072060-A1 | Organic Compounds | GABRB3, GABRB2, GABRB1 | PLA2G2A 4087/4885PLA2G5 4475/4885NOD1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.